Blinatumomab: Phase II started

In June, Micromet began an open-label, German Phase II trial to evaluate 15, 30 or 60 µg/m 2/day of IV blinatumomab in 21 patients. AstraZeneca’s MedImmune Inc. subsidiary licensed North American righ...